Research1 week ago 6 min read
Meta-analysis: GLP-1 class effects on cardiovascular and renal outcomes
A new pooled analysis covers 14 trials and over 90,000 participants.
by Editorial team
Scope
The meta-analysis pooled 14 cardiovascular outcome trials of GLP-1 receptor agonists, covering more than 90,000 adults with type 2 diabetes or obesity.
Outcomes included major adverse cardiac events, kidney disease progression, and mortality.
Findings
The class showed consistent reductions in MACE (relative risk ~0.86) and slowed progression of kidney disease.
All-cause mortality was reduced by roughly 12% versus comparators.
Limitations
Individual drugs varied in effect size — class summaries can hide product-specific differences.
Most participants had elevated cardiovascular risk; benefits may differ in healthier populations.